Orchestra BioMed postpones Virtue SAB pivotal study to 2024 amid Terumo negotiations

Orchestra BioMed Holdings, Inc.

Filed registration statement for resale of shares/warrants; not seeking additional capital.
Negotiating with Terumo to restructure milestone payments and modify distribution agreement.
Virtue ISR-US pivotal study initiation postponed to 2024 due to ongoing negotiations.
If negotiations not satisfactory, clinical/commercial plans for Virtue SAB may be further affected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.